Drug usage and costs of inpatients with angina in Karamay Central Hospital in 2014_Chinese Journal of Evidence-Based Medicine

Authors：

KUANG Liping ¹ , YU Jiajie ² ,  WU Min ¹ ,  LI Youping ² , ZHANG Weidong ¹ , XU Ting ³ , WANG Guotuan ¹ , LU Jing ³ , FANG Yiqing ¹ , SU Guanyue ²

1. Department of Pharmacy, Karamay Central Hospital, Karamay, 834000, P.R.China;
2. Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, 610041, P.R.China;
3. Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, 610041, P.R.China;

Corresponding author：

WU Min, Email: 1109637804@qq.com.cn; LI Youping, Email: yzmylab@hotmail.com

Keywords：

Inpatient; Angina; Evidence-based pharmacy; Rational drug use

DOI：

10.7507/1672-2531.201610066

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate drug usage and costs of angina inpatients in Karamay Central Hospital in 2014 and to provide evidence and reference for evidence-based pharmacy study of single disease in circulation system. Methods The information of drug use and expenditure of angina inpatients were collected from the hospital information system (HIS). We analyzed the data including frequency, proportion and cumulative proportion by Excel 2007 software. Results We included 351 angina inpatients in Karamay Central Hospital in 2014 whose average age was 69.44±10.65 years old. Fifty-one kinds of drugs were used for angina therapy. The expenditure of drugs was 122.46 yuan per person. The symptomatic treatment drugs included 11 kinds of drugs. The top 3 usage drugs were isosorbide denigrates, aspirin, nitroglycerin. The secondary prevention medicines included 35 kinds of drugs, and were prescribed for 1 953 times; the anti-hypertensive drugs were most prescribed. The Chinese patent medicine were prescribed for 69 times. The compound Danshen dripping pill was the most prescribed drug. In total expenditure, the cost of clopidogrel, atorvastatin, irofiban ranked top three. Rivaroxaban, tirofiban, low molecular weight heparin were the top 3 drugs for per-time expenditure. Conclusion The top 3 used drugs are isosorbide denigrates, aspirin, nitroglycerin for angina inpatients in Karamay Central Hospital in 2014, while the top 3 total expenditure drugs are clopidogrel, atorvastatin and irofiban.

Citation： KUANG Liping, YU Jiajie, WU Min, LI Youping, ZHANG Weidong, XU Ting, WANG Guotuan, LU Jing, FANG Yiqing, SU Guanyue. Drug usage and costs of inpatients with angina in Karamay Central Hospital in 2014. Chinese Journal of Evidence-Based Medicine, 2017, 17(8): 899-902. doi: 10.7507/1672-2531.201610066 Copy

1.	中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 慢性稳定性心绞痛诊断与治疗指南. 中华心血管病杂志, 2007, 35(3): 195-206.
2.	Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease. J Am Coll Cardiol, 2012, 60(24): 44-164.
3.	Task Force Members, Montalescot G, Sechtem U, et al. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J, 2013, 34(38): 2949-3003.
4.	Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol, 2016, 68(10): 1082-1115.
5.	Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. J Am Coll Cardiol, 2011, 58(24): 44-122.
6.	Task Force members. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J, 2014, 35(37): 2541-2619.

1. 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 慢性稳定性心绞痛诊断与治疗指南. 中华心血管病杂志, 2007, 35(3): 195-206.
2. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease. J Am Coll Cardiol, 2012, 60(24): 44-164.
3. Task Force Members, Montalescot G, Sechtem U, et al. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J, 2013, 34(38): 2949-3003.
4. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol, 2016, 68(10): 1082-1115.
5. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. J Am Coll Cardiol, 2011, 58(24): 44-122.
6. Task Force members. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J, 2014, 35(37): 2541-2619.

Chinese Journal of Evidence-Based Medicine

Drug usage and costs of inpatients with angina in Karamay Central Hospital in 2014

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content